September 10, 2025Hematology ReportsOpen Access

TKI Use and Treatment-Free Remission in Chronic Myeloid Leukemia: Evidence from a Regional Cohort Study in the Canary Islands

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational study shows 73.2% maintained remission at 36 months in patients with CML, indicating TKI use supports treatment-free remission.

Of the 107 patients attempting treatment-free remission, 73.2% maintained remission at 36 months.
In this cohort, 58.3% achieved molecular response grade 2 within the first year, reflecting effective TKI therapy.
Retrospective observational study analyzed outcomes for patients with chronic myeloid leukemia diagnosed between 2007 and 2023.
Findings underscore the importance of molecular monitoring in chronic myeloid leukemia to optimize treatment outcomes.

Sánchez-Sosa et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational study shows 73.2% maintained remission at 36 months in patients with CML, indicating TKI use supports treatment-free remission.